Neuromyelitis optica
Conditions
Interventions
Case series:Mycophenolate Mofetil
Sponsors
The third affiliated hospital,Sun Yat-sen university
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) 2006 NMO diagnostic criteria or NMOSD criteria; (2) serum NMO-IgG(+) (HEK 293 cells transfection method); (3) aged 18-65 years old, men and women; (4) relapse frequency: two or more attacks in the prior two years, one or more in the recent one year; (5) EDSS less than 7.0, and at least one eye visual acuity of 20/100; (6) written informed consent signed.
Exclusion criteria
Exclusion criteria: (1) using other immunosuppressants, such as cyclophosphamide, cyclosporin A,azathioprine, methotrexate; (2) with concomitant diseases: transaminase 2 times more than normal ceiling; The WBC <4*10^9/L, HGB <80 g/L, PLT <100*10^9/L; (3) with severe cardiovascular, liver, kidney and other important organs and blood, endocrine system diseases; (4) with immunodeficiency, with uncontrolled infections and active gastrointestinal diseases (such as stomach ulcers, etc.); (5) women of childbearing agewith postive urine pregnancy test, lactatin; (6) being allergic to mycophenolate mofetil and prednisone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| annual relapse rate; | — |
Countries
China
Contacts
Public ContactQiu Wei
Outcome results
None listed